

for the 5' side. This use is illustrative for this figure only and should not be used to interpret the claims, which us the Y and X designations taught in this specification.

Figure 2A shows a modified compound (X) according to the invention and oligonucleotides containing this compound.

Figure 2B shows the results of spleen assays using oligonucleotides including the modified compound (X) of Figure 2A.

Figure 3A shows another modified compound (X) according to the invention and oligonucleotides containing this compound.

Figure 3B shows the results of spleen assays using oligonucleotides including the modified compound (X) of Figure 3A.


REMARKS

The Description of the Drawings has been amended to be consistent with and more accurately delineate the formal drawings filed herewith with a petition pursuant to 37 C.F.R. §1.182. No new matter has been added as support for the amendments is found in the drawings and description of the drawings on page 6 as originally filed.

Applicants believe no fees are due at this time. However, please charge any fees or credit any overpayment to Deposit Account No. 08-0219.

Respectfully submitted,

HALE AND DORR LLP



Ann-Louise Kerner, Ph.D.

Registration No. 33,523

Attorney for Applicants

60 State Street
Boston, MA 02109
Tel. (617) 526-6000
Fax (617) 526-5000

Date: August 10, 2001